RecruitingCervical Cancer

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Eligible age

18+ yrs

Accepts

Women

Locations

28 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.

Sponsor: GOG Foundation

You may qualify if…

✓ 1. Patient must have histologically confirmed adenocarcinoma (usual/classic/NOS), squamous cell carcinoma, adenosquamous carcinoma (Including glassy cell)
✓ 2. Patient must be FIGO Stage IA2, IBI, IB2 (2018 staging) without evidence of definitive parametrial, vaginal, nodal or distant metastases on exam or imaging. Patients with tumor size less than or equal to 4 cm confirmed on MRI prior to randomization are eligible.
✓ 3. Patient must have uterine size \<12 cm AND felt to be appropriate for vaginal delivery of the specimen per investigator.
✓ 4. Patient must be suitable surgical candidate with preoperative assessments such as labs and EKG performed per institutional standard and agree to be randomized to undergo open or robotic radical (or simple) hysterectomy.
✓ NOTE: Simple hysterectomy will be allowed in patients who meet the following criteria:
✓ 1. pelvic MRI must demonstrate a maximal tumor size of 2 cm or less AND
✓ 2. less than 50% stromal invasion on MRI if tumor present or less than 10 mm of stromal invasion if an excisional (cold knife or LEEP) has been performed.
✓ Submission of source documents in the GOG Partners Source Document Portal will be required prior to randomization for review and confirmation of simple hysterectomy being met (see Section 6.0 for instructions).

You may not qualify if…

✕ 1. Patients with any tumor histology other than those listed above, specifically excluding the following histologies: neuroendocrine, other adenocarcinoma (gastric type, endometrioid, clear cell, serous, signet ring, minimal deviation)
✕ 2. Patients with FIGO stage 1A1, IB3, II-IV (2018 staging).
✕ 3. Patient with inability to receive an MRI.
✕ 4. Patients with a tumor size greater than 4cm or on MRI confirmed prior to randomization are excluded. Patients with definite evidence of vaginal/parametrial involvement on MRI are excluded; if MRI findings are not definitive, then clinical examination must also not reveal parametrial or vaginal extension).
✕ 5. Patients with evidence of metastatic disease (imaging or histologically positive lymph nodes).
✕ 6. Patients with a history of prior pelvic or abdominal radiotherapy.
✕ 7. Patients with a prior malignancy \< 5 years from enrollment with the exception of non-melanoma skin cancer.
✕ 8. Patients who are unable to withstand prolonged lithotomy or steep trendelenberg.